Adesh Kaul - Basilea Pharmaceutica Chief Officer
| BPMUF Stock | USD 44.45 0.00 0.00% |
Executive
Mr. Adesh Kaul will be appointing as a Chief Financial Officer of the company, Effective April 10, 2019. e is currently the Chief Corporationrationrate Development Officer and is a member of the Management Committee of Basilea. Mr. Kaul previously held the position of Head of Corporationrationrate Development. He joined Basilea in 2009 and served as Head Business Development, Licensing Investor Relations and as Head Public Relations Corporationrationrate Communications. From 2015 to 2016, he held the positions of CFO and Head Corporationrationrate Development at Polyphor AG. From 2006 to 2009 Mr. Kaul was senior financial analyst at Neue Zrcher Bank and before that he held several senior executive positions in general management and in sales marketing at Genedata AG since 2019.
| Age | 49 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Phone | 41 61 606 11 11 |
| Web | https://www.basilea.com |
Basilea Pharmaceutica Management Efficiency
The company has return on total asset (ROA) of 0.0261 % which means that it generated a profit of $0.0261 on every $100 spent on assets. This is way below average. Basilea Pharmaceutica's management efficiency ratios could be used to measure how well Basilea Pharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 12 records | EXECUTIVE Age | ||
| Avraham Gabay | Biomx Inc | 38 | |
| Dolly Tyan | Aditxt Inc | N/A | |
| MS MD | Aditxt Inc | N/A | |
| Riccardo Panicucci | NRX Pharmaceuticals | 62 | |
| Graeme Currie | Pasithea Therapeutics Corp | 57 | |
| Mike Shankman | Lexaria Bioscience Corp | N/A | |
| Matthew Duffy | NRX Pharmaceuticals | 61 | |
| Nelson CPA | Lexaria Bioscience Corp | 45 | |
| Carlos Carillo | SAB Biotherapeutics | N/A | |
| Nicolas Fellmann | Biophytis | 56 | |
| Edouard Bieth | Biophytis | N/A | |
| MD MBA | SAB Biotherapeutics | 51 | |
Management Performance
| Return On Asset | 0.0261 |
Basilea Pharmaceutica Leadership Team
Elected by the shareholders, the Basilea Pharmaceutica's board of directors comprises two types of representatives: Basilea Pharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Basilea. The board's role is to monitor Basilea Pharmaceutica's management team and ensure that shareholders' interests are well served. Basilea Pharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Basilea Pharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lutz Wevelsiep, Head Affairs | ||
| Adesh Kaul, Chief Officer | ||
| Damian Heller, Gen Sec | ||
| Gerrit Hauck, Chief Officer | ||
| David Veitch, Chief Commercial Officer, Member of the Management Committee | ||
| Ursula Eberhardt, Head HR | ||
| Marc MD, Chief Officer | ||
| Peer Schroder, Head Relations | ||
| Dietrich Stber, Head Services | ||
| Laurenz Kellenberger, Chief Scientific Officer |
Basilea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Basilea Pharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | 0.0261 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 724.26 M | |||
| Shares Outstanding | 11.93 M | |||
| Shares Owned By Insiders | 3.07 % | |||
| Shares Owned By Institutions | 29.13 % | |||
| Price To Earning | 200.00 X | |||
| Price To Sales | 4.09 X | |||
| Revenue | 148.12 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Basilea Pharmaceutica in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Basilea Pharmaceutica's short interest history, or implied volatility extrapolated from Basilea Pharmaceutica options trading.
Pair Trading with Basilea Pharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Basilea Pharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Basilea Pharmaceutica will appreciate offsetting losses from the drop in the long position's value.Moving against Basilea Pink Sheet
| 0.79 | CSLLY | CSL | PairCorr |
| 0.77 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.76 | VRTX | Vertex Pharmaceuticals | PairCorr |
| 0.75 | CMXHF | CSL Limited | PairCorr |
| 0.65 | REGN | Regeneron Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Basilea Pharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Basilea Pharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Basilea Pharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Basilea Pharmaceutica AG to buy it.
The correlation of Basilea Pharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Basilea Pharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Basilea Pharmaceutica moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Basilea Pharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Basilea Pharmaceutica AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Basilea Pink Sheet analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |